Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02328105 · ClinicalTrials.gov registry record · Phase 2
LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02328105 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 11 participants.
The verdict
NCT02328105, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
ABRAXANE, based on results from prior studies, is a promising drug in squamous cell carcinoma of the lung. This study will help to explore the combination of ABRAXANE and carboplatin more thoroughly in the subgroup of patients who had the best response in prior studies as well as determine whether there are any biomarkers which can predict for response.
Interventions
- DRUG Carboplatin
- DRUG Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-12 |
| Est. Completion | 2019-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02328105
The ClinicalTrials.gov registry entry for NCT02328105 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT02328105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02328105 about?
NCT02328105 is a clinical study titled "LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer". ABRAXANE, based on results from prior studies, is a promising drug in squamous cell carcinoma of the lung. This study will help to explore the combination of ABRAXANE and carboplatin more thoroughly in the subgroup of patients who had the best response in prior studies as well as determine whether t...
What is the current status of trial NCT02328105?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2014-12. Estimated completion is 2019-12-06.
What interventions are being tested in trial NCT02328105?
The interventions under investigation include: Carboplatin (DRUG), Abraxane (DRUG).
Who is sponsoring clinical trial NCT02328105?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.